An open study of interferon in HIV-antibody-positive men
Autor: | Nigel Blackburn, John Craske, Andrew J. Turner, Michael R. Potter, Michael E. Ellis, John Shipman, Mansel R. Haeney |
---|---|
Rok vydání: | 1989 |
Předmět: |
Adult
CD4-Positive T-Lymphocytes Male HIV antibody positive HIV Antigens Injections Subcutaneous Immunology HIV Core Protein p24 Gene Products gag HIV Infections Self Administration Disease Interferon alpha-2 T-Lymphocytes Regulatory Leukocyte Count Interferon HIV Seropositivity medicine Humans Immunology and Allergy Lymphocytes business.industry Viral Core Proteins Interferon-alpha virus diseases Middle Aged medicine.disease Thrombocytopenic purpura Recombinant Proteins Open study Infectious Diseases medicine.anatomical_structure Interferon Type I Nail (anatomy) business Hiv disease medicine.drug |
Zdroj: | AIDS. 3:851-854 |
ISSN: | 0269-9370 |
DOI: | 10.1097/00002030-198912000-00012 |
Popis: | Alpha-2a-recombinant interferon (Roferon A) was given subcutaneously in a dose of 3 mega units twice weekly for 15-18 months to 14 HIV-antibody-positive, p24-antigen-negative men with minimal HIV-related disease. Interferon was well-tolerated and safe. Although there was either improvement or lack of deterioration initially in 22 out of 26 HIV disease markers, including lymphadenopathy, thrombocytopenic purpura and nail fungal infection, there were 11 instances of HIV disease indicators appearing during the study. At 15 months, six patients were withdrawn from the study because of clinical and immunological deterioration. |
Databáze: | OpenAIRE |
Externí odkaz: |